On the recordMay 3, 2021
Policies like referencing pricing and government price-settings will effectively turn our biopharma industry to a risk-averse, think-inside-the-box-rather-than-outside-the-box commodity industry.
Source
congress.govPolicies like referencing pricing and government price-settings will effectively turn our biopharma industry to a risk-averse, think-inside-the-box-rather-than-outside-the-box commodity industry.
McKinley warns that certain policies could harm innovation in the biopharma sector.
Share
More from David McKinley
Now, Assistant Administrator, Section 902--just in your opinion, I know that you haven't crafted the bill, but it is out there before us--Section 902 of the Clean Future Act restricts the building or expansion of American plastic…
But it appears to me the policies that have been put forth in the last ten months are doing diametrically opposite.
I will never vote for a mandate, because that is just going to make more resistance to the vaccine, and more distrust of the Federal Government.
I think what you are doing by your memo is you are only going to make it worse.